Does treatment of Raynaud 's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improve endothelial cell injury in systemic sclerosis?
PGE1alpha-cyclodextrin reduces RP symptoms and plasma levels of the markers of endothelial injury in SSc, suggesting that an improvement of endothelial dysfunction contributes to its prolonged therapeutic effect.
It is concluded that short-term creatine supplementation does not alter the responses of growth hormone, testosterone, and cortisol to a single bout of heavy resistance training.